OBJECTIVE: To detect matrix metalloproteinase (MMP)-9 in serum and CSF and determine relationships between MMP activity and severity of disease, duration of clinical signs, and duration of hospitalization in dogs with acute intervertebral disk disease (IVDD). ANIMALS: 35 dogs with acute IVDD and 8 clinically normal control dogs. PROCEDURE: CSF and serum were collected from affected and control dogs. Zymography was used to detect MMP-9. RESULTS: Activity of MMP-9 in CSF was detected in 6 of 35 dogs with IVDD; activity was significantly more common in dogs with duration of signs < 24 hours. Paraplegic dogs were more likely to have MMP-9 activity in the CSF than non-paraplegic dogs. No significant difference in hospitalization time was detected in dogs with IVDD between those with and without activity of MMP-9 in the CSF. Serum MMP-9 was detected more frequently in dogs with IVDD than in control dogs. CONCLUSIONS AND CLINICAL RELEVANCE: Data were consistent with results of experimental rodent spinal cord injury studies that indicate that MMP-9 is expressed early during secondary injury.
OBJECTIVE: To detect matrix metalloproteinase (MMP)-9 in serum and CSF and determine relationships between MMP activity and severity of disease, duration of clinical signs, and duration of hospitalization in dogs with acute intervertebral disk disease (IVDD). ANIMALS: 35 dogs with acute IVDD and 8 clinically normal control dogs. PROCEDURE: CSF and serum were collected from affected and control dogs. Zymography was used to detect MMP-9. RESULTS: Activity of MMP-9 in CSF was detected in 6 of 35 dogs with IVDD; activity was significantly more common in dogs with duration of signs < 24 hours. Paraplegic dogs were more likely to have MMP-9 activity in the CSF than non-paraplegic dogs. No significant difference in hospitalization time was detected in dogs with IVDD between those with and without activity of MMP-9 in the CSF. Serum MMP-9 was detected more frequently in dogs with IVDD than in control dogs. CONCLUSIONS AND CLINICAL RELEVANCE: Data were consistent with results of experimental rodent spinal cord injury studies that indicate that MMP-9 is expressed early during secondary injury.
Authors: Kimberly M Anderson; C Jane Welsh; Colin Young; Gwendolyn J Levine; Sharon C Kerwin; C Elizabeth Boudreau; Ismael Reyes; Armando Mondragon; John F Griffin; Noah D Cohen; Jonathan M Levine Journal: J Neurotrauma Date: 2015-07-17 Impact factor: 5.269
Authors: Amanda R Taylor; C Jane Welsh; Colin Young; Erich Spoor; Sharon C Kerwin; John F Griffin; Gwendolyn J Levine; Noah D Cohen; Jonathan M Levine Journal: J Neurotrauma Date: 2014-07-08 Impact factor: 5.269
Authors: Jonathan M Levine; Gwendolyn J Levine; Brian F Porter; Kimberly Topp; Linda J Noble-Haeusslein Journal: J Neurotrauma Date: 2011-03-25 Impact factor: 5.269
Authors: Sarah A Moore; Nicolas Granger; Natasha J Olby; Ingo Spitzbarth; Nick D Jeffery; Andrea Tipold; Yvette S Nout-Lomas; Ronaldo C da Costa; Veronika M Stein; Linda J Noble-Haeusslein; Andrew R Blight; Robert G Grossman; D Michele Basso; Jonathan M Levine Journal: J Neurotrauma Date: 2017-03-22 Impact factor: 5.269
Authors: Jonathan M Levine; Noah D Cohen; Michael Heller; Virginia R Fajt; Gwendolyn J Levine; Sharon C Kerwin; Alpa A Trivedi; Thomas M Fandel; Zena Werb; Augusta Modestino; Linda J Noble-Haeusslein Journal: PLoS One Date: 2014-05-01 Impact factor: 3.240